Pleomorphic adenoma cytology. Prosztata adenoma rák 3. fokozatú kezelés
Prosztata adenoma rák 3. Currently, based on these parameters, adenomas are characterized as "non-advanced or advanced" and patient surveillance is adjusted accordingly.
The aim of this study was to investigate the correlation between the KRAS mutations and characteristics of non-advanced and advanced colorectal adenomas for predicting the risk of increased malignant potential of adenomas that may influence the decision to offer follow-up endoscopic surveillance. We used a mutagenic polymerase chain reaction - restriction fragment length polymorphism method to determine KRAS mutations in colorectal sporadic polypoid adenomas 51 non-advanced- advanced adenomas and in 40 early colorectal carcinomas.
The method of mutation detection was validated according to recommendation for KRAS mutation testing in colorectal carcinoma of the European Quality Assurance Program. Evaluation of pathological characteristics was performed according prostatitis chabret European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis. There was no significant difference in association of KRAS mutation with age, gender, location among non-advanced- and advanced adenomas and early carcinomas.
KRAS mutation is very strongly associated with a villous architecture and through villous component expansion, KRAS mutations may increase risk of tumor progression in sporadic pleomorphic adenoma cytology polypoid adenomas. Lásd még.